Compare BioNTech SE - ADR (BNTX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Jumia Technologies AG - ADR — how do they compare? BioNTech SE - ADR trades at $93.34 (market cap $23.31B), while Jumia Technologies AG - ADR trades at $6.3 (market cap $719.58M). The key difference: BioNTech SE - ADR is far larger — about 32.4× Jumia Technologies AG - ADR's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | JMIA | |
|---|---|---|
Market Cap | $23.31B | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $14.60 |
52-Week Low | $83.89 | $5.69 |
Enterprise Value | $6.60B | $666.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
JMIA trades at $6.245, up 4.08% on the day, amid a bearish technical signal and mixed fundamentals. The company reported revenue of $188.93M for 2025 with a gross profit margin of 54.75%, but net losses persist, and recent earnings have missed expectations. Analyst consensus is strongly bullish with 71.43% buy ratings, while technical indicators show selling pressure.
The outlook hinges on JMIA's path to profitability, targeting Q4 2026 breakeven and 2027 profitability. Risks include high cash burn and competitive pressures, but gross profit growth and strategic partnerships offer potential upside for patient investors focused on the African e-commerce market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
